Blackhawk Capital Partners LLC. Has $274,000 Stock Holdings in Incyte Co. (NASDAQ:INCY)

Blackhawk Capital Partners LLC. decreased its holdings in Incyte Co. (NASDAQ:INCY) by 17.7% during the 4th quarter, HoldingsChannel reports. The firm owned 3,960 shares of the biopharmaceutical company’s stock after selling 852 shares during the quarter. Blackhawk Capital Partners LLC.’s holdings in Incyte were worth $274,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Point72 Asset Management L.P. bought a new position in Incyte in the third quarter valued at about $156,611,000. Mizuho Securities USA LLC boosted its stake in shares of Incyte by 13,814.7% in the 3rd quarter. Mizuho Securities USA LLC now owns 2,000,100 shares of the biopharmaceutical company’s stock valued at $132,207,000 after purchasing an additional 1,985,726 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Incyte by 29.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,609,220 shares of the biopharmaceutical company’s stock valued at $106,369,000 after purchasing an additional 364,169 shares in the last quarter. Bridgewater Associates LP grew its holdings in shares of Incyte by 142.8% during the 3rd quarter. Bridgewater Associates LP now owns 308,632 shares of the biopharmaceutical company’s stock valued at $20,401,000 after purchasing an additional 181,504 shares during the last quarter. Finally, Ieq Capital LLC increased its position in Incyte by 1,342.5% during the 4th quarter. Ieq Capital LLC now owns 138,536 shares of the biopharmaceutical company’s stock worth $9,569,000 after purchasing an additional 128,932 shares in the last quarter. Institutional investors and hedge funds own 96.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on INCY shares. Cantor Fitzgerald restated a “neutral” rating on shares of Incyte in a research report on Friday, January 10th. The Goldman Sachs Group boosted their price objective on Incyte from $63.00 to $70.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. William Blair reaffirmed an “outperform” rating on shares of Incyte in a report on Friday, December 13th. JMP Securities reissued a “market perform” rating on shares of Incyte in a research note on Tuesday, February 11th. Finally, Citigroup lowered their price objective on Incyte from $97.00 to $88.00 and set a “buy” rating for the company in a research note on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $75.25.

Incyte Stock Performance

Shares of INCY opened at $74.01 on Tuesday. The firm’s fifty day simple moving average is $71.32 and its two-hundred day simple moving average is $69.60. Incyte Co. has a 12 month low of $50.35 and a 12 month high of $83.95. The company has a current ratio of 1.97, a quick ratio of 1.94 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $14.32 billion, a P/E ratio of 274.12, a price-to-earnings-growth ratio of 0.41 and a beta of 0.70.

Incyte (NASDAQ:INCY) last announced its earnings results on Monday, February 10th. The biopharmaceutical company reported $1.09 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.48). Incyte had a net margin of 0.77% and a return on equity of 0.05%. As a group, analysts predict that Incyte Co. will post 4.86 EPS for the current year.

Insider Transactions at Incyte

In related news, insider Thomas Tray sold 650 shares of the stock in a transaction on Friday, December 13th. The shares were sold at an average price of $70.64, for a total transaction of $45,916.00. Following the transaction, the insider now directly owns 23,962 shares of the company’s stock, valued at $1,692,675.68. This represents a 2.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Vijay K. Iyengar sold 6,043 shares of the firm’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $75.38, for a total transaction of $455,521.34. Following the completion of the sale, the executive vice president now owns 30,658 shares of the company’s stock, valued at $2,311,000.04. The trade was a 16.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 19,695 shares of company stock valued at $1,444,356 in the last quarter. 17.60% of the stock is currently owned by company insiders.

Incyte Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.